💊Pharmaconomics
← Calendar  ·  All GSK catalysts
GSK
GSK plc
Catalyst AI-extracted
Efimosfermin (FGF21)
liver disease MASH
Resolved
69days ago
Catalyst readout · Apr 29, 2026
What's at stake A key catalyst for Efimosfermin (FGF21) (liver disease MASH) is expected Apr 29, 2026.
Primary source · SEC 6-K verified 12h ago
“Efimosfermin (FGF21) granted US Breakthrough and EU PRIME designations for liver disease MASH.”
Add to calendar Post on X Reddit

Provenance

1 source on file.

Link copied ✓